Positive Surgical Margins in RCC More Common Among African Americans

Article

African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients.

African American patients with localized renal cell carcinoma (RCC) who underwent robotic partial nephrectomy (RPN) were at an increased risk for positive surgical margins compared with white patients, according to the results of a population-based study published online in Urologic Oncology: Seminars and Original Investigations.

According to the study, RPN has become the preferred surgical approach for patients with T1 RCC because of better surgical outcomes and lower perioperative morbidity compared with open or laparoscopic procedures. However, RPN is associated with greater rates of positive surgical margins.

“It is well recognized that racial disparities exist in the incidence, access to care, prognosis, and survival outcomes of patients with RCC,” wrote Victor S. Chen, BS, of Case Western Reserve University School of Medicine in Cleveland, Ohio, and colleagues. “However, little is known of whether the quality of care for RPN varies by race. Therefore, we sought to assess the association between race and margin status among patients undergoing RPN for T1 RCC in a large population-based cohort study.”

The researchers used data from the National Cancer Database to identify patients with localized RCC who underwent RPN from 2010 to 2013. They identified 12,515 patients, of which 8.3% had positive surgical margins.

The rate of positive surgical margins was higher at nonacademic hospitals compared with academic hospitals (10.4% vs 6.8%; P < .001). According to the researchers this finding “supports the volume-outcome relationship where higher volume surgeons may have greater clinical experience to perform RPN in anatomically complex renal tumors and thus have lower rates of positive surgical margins following RPN.”

Significantly more African American patients had positive surgical margins compared with white patients (10.8% vs 7.9%; P = .005). A multivariable analysis showed that African American patients were 40% more likely than white patients to have positive surgical margins (odds ratio, 1.40; P = .008).

“Although the clinical relevance of positive surgical margins after PN for RCC has been questioned, a recent retrospective cohort study demonstrated that positive surgical margins were associated with greater risk of distant relapse,” the researchers wrote. “In addition, the surgical margin status is widely regarded as a well-known quality indicator.”

From 2010 to 2013, the proportion of African American patients with positive surgical margins did decline from 12.5% to 8.3%. African Americans also had a greater proportion of larger tumor size compared with other races (18.8% vs 15.7%; P = .021).

“These results suggest potential differences in quality of care, and diffusion of advanced treatment technology varies by race,” the researchers wrote. “Further study is needed to delineate potential actionable causes for the disparities observed in this study and design interventions to improve quality of care for minority men.”

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content